GSK172981, with the CAS number 1133705-99-3, is a chemical compound that has been studied primarily for its potential therapeutic applications. It belongs to a class of compounds known as small molecules, which are often utilized in drug development due to their ability to interact with biological targets. The specific characteristics of GSK172981 include its molecular structure, which is designed to modulate certain biological pathways, potentially offering benefits in treating various diseases. The compound's solubility, stability, and bioavailability are critical factors that influence its efficacy and safety profile. Additionally, GSK172981 may exhibit specific pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), which are essential for understanding its behavior in biological systems. Research on this compound may also focus on its mechanism of action, potential side effects, and interactions with other drugs. Overall, GSK172981 represents a promising candidate in the field of medicinal chemistry, although further studies are necessary to fully elucidate its characteristics and therapeutic potential.

GSK172981 is a  non-peptide tachykinin NK3 receptor antagonist. GSK172981 demonstrated high affinity for recombinant human (pK(i) value 7.7) and native guinea pig (pK(i) value 7.8) tachykinin NK(3) receptors. In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA(2)=7.2) at cloned human tachykinin NK(3) receptor. GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pK(B)=8.1).  GSK172981 is potentially useful in the treatment of schizophrenia.

GSK172981

1133705-99-3: GSK172981, with the CAS number 1133705-99-3, is a chemical compound that has been studied primarily for its potential therapeutic applications. It belongs to a class of compounds known as small molecules, which are often utilized in drug development due to their ability to interact with biological targets. The specific characteristics of GSK172981 include its molecular structure, which is designed to modulate certain biological pathways, potentially offering benefits in treating various diseases. The compound's solubility, stability, and bioavailability are critical factors that influence its efficacy and safety profile. Additionally, GSK172981 may exhibit specific pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), which are essential for understanding its behavior in biological systems. Research on this compound may also focus on its mechanism of action, potential side effects, and interactions with other drugs. Overall, GSK172981 represents a promising candidate in the field of medicinal chemistry, although further studies are necessary to fully elucidate its characteristics and therapeutic potential.

<p>GSK172981: NK3 receptor antagonist with high affinity (human PKI 7.7; guinea pig 7.8), potentially treats schizophrenia.</p>

CAS 1133705-99-3

GSK172981

GSK172981

Ref: TM-T32004